John P. Micha

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Survival rate comparisons amongst cervical cancer patients treated with an open, robotic-assisted or laparoscopic radical hysterectomy: A five year experience

Alberto A. Mendivil, Mark A. Rettenmaier, Lisa N. Abaid et al. · Surgical Oncology · 2015 · 120 citations

Gynecologic Surgery, Laparoscopy, Surgical Oncology +14

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

John P. Micha, Bram H. Goldstein, Mark A. Rettenmaier et al. · International Journal of Gynecological Cancer · 2007 · 106 citations

Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions

John P. Micha, Bram H. Goldstein, Connie L. Birk et al. · Gynecologic Oncology · 2005 · 86 citations

Oncology, Medicine, Gynecology +8

Chemotherapy and patient co-morbidity in ventral site hernia development

Mark A. Rettenmaier, Lisa N. Abaid, John V. Brown et al. · Journal of Gynecologic Oncology · 2009 · 58 citations · Full text